4th Jan 2016 15:55
GlaxoSmithKline plc
Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons
I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares ('ADSs') of GlaxoSmithKline plc (the 'Company').
On 31 December 2015, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £13.83 per Ordinary Share, and notional ADSs at a price of $40.98 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 October 2015 to 31 December 2015:
Non Executive Director | Ordinary Shares | No. of ADSs |
Sir Philip Hampton | 3,163.413 | |
Professor Sir Roy Anderson | 655.278 | |
Vindi Banga | 1,536.515 | |
Dr Stephanie Burns | 410.403 | |
Stacey Cartwright | 519.704 | |
Lynn Elsenhans | 912.543 | |
Judy Lewent | 398.332 | |
Sir Deryck Maughan | 1,110.502 | |
Dr Daniel Podolsky | 832.877 | |
Urs Rohner | 610.087 | |
Hans Wijers | 519.704 | |
In addition, on 31 December 2015, Mr Banga was allocated 566.213 notional Ordinary Shares at a price of £12.51 per Ordinary Share in respect of the period of service from 1 September 2015 to 30 September 2015.
The Company and the Non-Executive Directors were informed of these allocations on 4 January 2016.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
4 January 2016
Related Shares:
Glaxosmithkline